Sama Therapeutics

We’re #hiring. Know anyone who might be interested?

Sama is hiring! Join us in shaping the future of mental health and clinical care with AI! We are looking for frontend, backend and platform engineers (f/m/d) to shape our platform for many fascinating use cases! Do you wish to be part of a team where you can learn, grow, and thrive? We are waiting for your application! Check the job descriptions here: https://lnkd.in/e4DPHTXe How to Apply: Send an email showcasing your strengths to franz@sama.ac - We're looking forward to receiving it and will get back to you within a few days.

We’ve been working with the R&D team at Anam over the last few months to create psychometric tools, using real time AI personas that can mimic healthcare provider interactions. Check out Caoimhe’s exclusive with Axios, and their demos at Anam.ai. https://lnkd.in/egjrkmdE https://lnkd.in/epEwjy5r Caoimhe Murphy

🚀 Exciting update! Sama Therapeutics has been accepted into not just one, but TWO of the most competitive accelerator programs for deep tech: Endless Frontier Labs at New York University, and Creative Destruction Lab (CDL). https://lnkd.in/egG3dER With admission rates of around 3-5%, these programs are incredibly selective. This double win comes on top of our recent acceptance into the NIH/MIT Bootcamps Substance Use Disorders venture fellows program. https://lnkd.in/ewiNtqar What does this mean for Sama Therapeutics? 1. Expanded networking in the AI/healthtech hubs of NYC, Seattle, and Boston 2. More strategic partnerships and R&D collaborations to finesse 3. Increased exposure to healthcare/pharma customers and business models 4. Access to industry consortia and valuable datasets We're looking forward to an autumn packed with growth, performance milestones, and new incubations for our team. -SamaThera AI 💙 💜 ps. to be honest, just needed more partner-AWS compute credits😉 Every bit helps when you're pushing the boundaries of AI-powered precision medicine! #DeepTech #Accelerators #EFL #CDL #MITBootcamps #AIinHealthcare #SamaTherapeutics

🎉 We're thrilled to share that Sama Therapeutics has been accepted into the prestigious Creative Destruction Lab (CDL) program at the University of Washington, Seattle, as part of the Computational Health Stream! https://lnkd.in/eZvAhg6k The CDL program is renowned for supporting massively scalable, seed-stage, high-impact, science- and technology-based startups, and we're incredibly grateful for this opportunity to collaborate with world-class mentors, strategic investors, and industry leaders to push the boundaries of generative AI-powered precision medicine. Thank you to the CDL folks for believing in our vision. We're excited to join such a dynamic community of entrepreneurs and look forward to making the most of this transformative experience. Let’s get to work!! 🚅 -The SamaThera AI Team 💙 💜 Shobi Ahmed, MD, PhD Adam Teed Dr. Franz Hell Tyler Moore Aurina Arnatkevičiūtė Alan Tucholka Russell Hanson Elias Mouchlianitis Priyal Sheth, MSc Eric Schultz Martijn Arns Sharmin Ghaznavi Adam Safron Karim El Kanbi Saurabh Sharma, MBA, MPH Avery Bedows Simarpreet Kamboj Emma Tung Kelly Kennedy ps. Not shy to disclose that we were admitted on our *third application, even as every year it's gotten more competitive, not less (CDL is more specialized than YC for deep tech: fundamental scientific discovery and equally difficult, its real-world translation into viable business models). #CDL #HealthTech #ComputationalHealth #CreativeDestructionLab #Seattle #UniversityOfWashington #Startups #SamaTherapeutics

A great merger of business and scientific strategy: Sama Therapeutics’s been invited to more than one “pre-competitive” consortia in the digital biomarker/health solutions space this year!

Sama Therapeutics is happy to be presenting at the 4th Annual Psychedelic Therapeutics & Drug Development Conference (https://lnkd.in/g5qk2AeY) on May 23-24, 2024 in Boston. We hope you can join us at this year's event. #psychedelics #psychedelicresearch #psychedelictherapy Day Two — 11:20AM May 24, 2024 Title: Fusing AI-models of Biometrics and Psychometrics to boost Psychedelic Drug Approvals — Shobi Ahmed, MD, Ph.D., Chief Executive Officer "Sama Therapeutics' cutting-edge AI platform is fusing and cross-validating biometric and psychometric data to identify novel digital biomarkers and endpoints for psychedelic drug development. We will use a series of data-driven case studies to demonstrate how leveraging these predictive models can reduce confounds like placebo functional unblinding and dose-dependent variation, and advance monitoring in real-time with state-based biomarkers for each patient's unique neurobiological and psychological profile."

Sama Therapeutics selected as a SXSW Pitch competition finalist from among hundreds of startups, in the Health category! 🏥 🚀

As 2023 draws to a close, we’re feeling extra grateful for our team, partners, and everything we've accomplished in the past 12 months. It's been a year marked by growth, innovation, and recognition: ✨ Team Expansion: We've welcomed 12 new members from 5 countries with 15 degrees to our interdisciplinary team, each bringing unique perspectives and expertise as we race towards our mission of ending trial-and-error in neuropsychiatry. 🚀 Business Traction: Our company valuation has soared 8.5x since we began fundraising in March 2022. This growth is a testament to the dedication of our team and the trust placed in us by partners like Mystic Ventures, Massachusetts General Hospital, Brainclinics Foundation, Damona Pharmaceuticals, Zeto, Reconnect Labs, IDUN Technologies, Capital Factory, and others that have supported us along the way. 🏆 IP Recognition: Our rapidly growing AI/ML platform intellectual property, codebase, and novel neurotechnology integrations distinguished us as leaders in the space, with achievements such as: - Ranking 1st, 2nd, 3rd, and 4th place in the international TD-Brain “clinically-actionable biomarker” challenge (link in comments). - Demonstrating groundbreaking predictive power across numerous datasets that is *50-150% better* than current trial-and-error standard of care. - Selection in the top 2-3% out of thousands of startups globally as “deep tech/health” finalists in multiple pitch competitions – including a major upcoming venue we’re not at liberty to announce until mid-January ;) Here's to the scientific discovery and opportunities that await in 2024! 🎉 Follow us here and on X @SamaNeurosci for more updates as we advance brain health. Happy holidays all!! #neuroscience #mentalhealth #machinelearning